Lexicon Pharmaceuticals (LXRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.07
- EPS estimate
- −$0.05
- EPS surprise
- −39.44%
- Revenue surprise
- −82.66%
- Revenue
- $692,000.00
- Revenue estimate
- $4.0M
- Reported
- Aug 6, 2026
Lexicon Pharmaceuticals reported Q2 2026 results on August 6, 2026. It posted a loss of $0.07 per share, wider than the $0.05 loss expected, a 39.44% miss. Revenue was $692,000, well below the $4.0 million consensus. A year earlier, in Q2 2025, Lexicon earned $0.01 per share on revenue of $28.9 million, so revenue fell about 98% year over year.
Revenue in the table is small and uneven. It stayed below $1 million a quarter through 2023 and between $1.1 million and $1.8 million in the first three quarters of 2024. Since then it has swung widely, from $26.6 million in Q4 2024 and $28.9 million in Q2 2025 to $1.3 million in Q1 2025 and $692,000 in the latest quarter. The annual loss was $0.61 per share in 2022, $0.80 in 2023, $0.64 in 2024 and $0.14 in 2025. Q2 2025 was the only profitable quarter in the table. Over the last 20 quarters, Lexicon beat the EPS estimate 15 times and missed five.
Lexicon reported Q3 between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.05 | −$0.07 | −39.44% | $692,000.00 | SEC |
| Q1 2026 | May 7, 2026 | −$0.03 | $0.00 | +100.00% | $21.1M | SEC |
| Q4 2025 | Mar 5, 2026 | −$0.07 | −$0.04 | +42.03% | $5.5M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.07 | −$0.04 | +39.39% | $14.2M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.08 | $0.01 | +113.33% | $28.9M | SEC |
| Q1 2025 | May 13, 2025 | −$0.10 | −$0.07 | +26.32% | $1.3M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.13 | −$0.09 | +29.30% | $26.6M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.16 | −$0.18 | −10.57% | $1.8M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.18 | −$0.17 | +3.95% | $1.6M | SEC |
| Q1 2024 | May 2, 2024 | −$0.18 | −$0.20 | −11.11% | $1.1M | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.22 | −$0.20 | +7.92% | $702,000.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.21 | −$0.21 | +2.19% | $162,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.17 | −$0.22 | −25.93% | $317,000.00 | SEC |
| Q1 2023 | May 2, 2023 | −$0.18 | −$0.17 | +5.19% | $24,000.00 | SEC |
| Q4 2022 | Mar 2, 2023 | −$0.13 | −$0.16 | −19.49% | $28,000.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.14 | −$0.13 | +7.21% | $39,000.00 | SEC |
| Q2 2022 | Aug 2, 2022 | −$0.16 | −$0.16 | +0.68% | $35,000.00 | SEC |
| Q1 2022 | May 5, 2022 | −$0.17 | −$0.16 | +3.44% | $37,000.00 | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.18 | −$0.17 | +7.00% | $14,000.00 | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.18 | −$0.16 | +9.91% | $23,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Lexicon Pharmaceuticals (LXRX) last report earnings?
Lexicon Pharmaceuticals last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did LXRX beat earnings estimates?
No. Lexicon Pharmaceuticals reported EPS of −$0.07 for Q2 2026 against a −$0.05 estimate — a 39.44% miss.
How much revenue did LXRX report last quarter?
Lexicon Pharmaceuticals reported $692,000.00 in revenue for Q2 2026, against a consensus estimate of $4.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.